|
US8168181B2
(en)
|
2006-02-13 |
2012-05-01 |
Alethia Biotherapeutics, Inc. |
Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
|
|
ES2397441T5
(es)
|
2006-02-13 |
2022-09-14 |
Daiichi Sankyo Co Ltd |
Secuencias polinucleotídicas y polipeptídicas implicadas en el proceso de remodelación ósea
|
|
CA2680237C
(en)
|
2007-03-27 |
2018-11-06 |
Sea Lane Biotechnologies, Llc |
Constructs and libraries comprising antibody surrogate light chain sequences
|
|
US20120128671A1
(en)
|
2009-05-13 |
2012-05-24 |
Lawrence Horowitz |
Neutralizing molecules to influenza viruses
|
|
SI2516469T1
(sl)
|
2009-12-22 |
2016-05-31 |
Roche Glycart Ag |
Protitelesa proti her3 in uporabe le-teh
|
|
WO2011136911A2
(en)
|
2010-04-09 |
2011-11-03 |
Aveo Pharmaceuticals, Inc. |
Anti-erbb3 antibodies
|
|
ME02637B
(me)
|
2010-08-20 |
2017-06-20 |
Novartis Ag |
Antitela za receptor 3 faktora rasta epiderma (her3)
|
|
TW201302793A
(zh)
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
|
US9217039B2
(en)
|
2010-11-01 |
2015-12-22 |
Symphogen A/S |
Anti-HER3 antibodies and compositions
|
|
ITRM20100577A1
(it)
|
2010-11-02 |
2012-05-03 |
Takis Srl |
Immunoterapia contro il recettore erbb-3
|
|
CA2828075A1
(en)
|
2011-03-11 |
2012-09-20 |
Merrimack Pharmaceuticals, Inc. |
Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
|
|
MX2013010444A
(es)
|
2011-03-15 |
2014-03-21 |
Merrimack Pharmaceuticals Inc |
Superar la resistencia a inhibidores de la via erbb.
|
|
AU2012245491C1
(en)
|
2011-04-19 |
2017-12-21 |
Merrimack Pharmaceuticals, Inc. |
Monospecific and bispecific anti-IGF-1R and anti-ErbB3 antibodies
|
|
WO2013016714A1
(en)
*
|
2011-07-28 |
2013-01-31 |
Sea Lane Biotechnologies |
Sur-binding proteins against erbb3
|
|
EP2748197A2
(en)
|
2011-08-26 |
2014-07-02 |
Merrimack Pharmaceuticals, Inc. |
Tandem fc bispecific antibodies
|
|
US9273143B2
(en)
|
2011-09-30 |
2016-03-01 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
|
|
PH12014500483A1
(en)
*
|
2011-09-30 |
2014-04-14 |
Regeneron Pharma |
Anti-erbb3 antibodies and uses thereof
|
|
JP6169085B2
(ja)
*
|
2011-10-06 |
2017-07-26 |
アベオ ファーマシューティカルズ， インコーポレイテッド |
抗ｅｒｂｂ３抗体に対する腫瘍応答の推定
|
|
RU2620068C2
(ru)
|
2011-11-23 |
2017-05-22 |
МЕДИММЬЮН, ЭлЭлСи |
Связывающие молекулы, специфичные по отношению к her3, и их применения
|
|
JP2015500830A
(ja)
*
|
2011-12-05 |
2015-01-08 |
ノバルティス アーゲー |
上皮細胞増殖因子受容体３（ｈｅｒ３）のドメインｉｉｉおよびドメインｉｖに対するｈｅｒ３の抗体
|
|
KR20140103135A
(ko)
*
|
2011-12-05 |
2014-08-25 |
노파르티스 아게 |
Her3의 도메인 ii에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체
|
|
ES2758433T3
(es)
*
|
2011-12-05 |
2020-05-05 |
Novartis Ag |
Anticuerpos contra el receptor 3 del factor de crecimiento epidérmico (HER3)
|
|
US9975956B2
(en)
|
2011-12-22 |
2018-05-22 |
I2 Pharmaceuticals, Inc. |
Surrogate binding proteins which bind DR4 and/or DR5
|
|
US9493562B2
(en)
|
2012-07-19 |
2016-11-15 |
Alethia Biotherapeutics Inc. |
Anti-Siglec-15 antibodies
|
|
AR094403A1
(es)
|
2013-01-11 |
2015-07-29 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos anti-her3
|
|
US9458245B2
(en)
|
2013-03-06 |
2016-10-04 |
Merrimack Pharmaceuticals, Inc. |
ANTI-C-MET tandem Fc bispecific antibodies
|
|
EP2821071A1
(en)
|
2013-07-04 |
2015-01-07 |
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) |
Compounds for breast cancer treatment
|
|
WO2015048008A2
(en)
|
2013-09-24 |
2015-04-02 |
Medimmune, Llc |
Binding molecules specific for her3 and uses thereof
|
|
US10035847B2
(en)
|
2013-10-02 |
2018-07-31 |
The Rockefeller University |
Amyloid protofibril antibodies and methods of use thereof
|
|
WO2015100459A2
(en)
|
2013-12-27 |
2015-07-02 |
Merrimack Pharmaceuticals, Inc. |
Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
|
|
WO2015138411A1
(en)
*
|
2014-03-10 |
2015-09-17 |
The Brigham And Women's Hospital, Inc. |
Anti-fibulin-3 antibodies and uses thereof
|
|
WO2015143123A2
(en)
|
2014-03-19 |
2015-09-24 |
Mackay Memorial Hospital Of Taiwan Presbyterian Church And Mackay Memorial Social Work Foundation |
Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof
|
|
BR112016020009A2
(pt)
|
2014-04-10 |
2017-10-17 |
Obi Pharma Inc |
anticorpo, composição farmacêutica, método para inibir a proliferação de células cancerígenas, hibridoma
|
|
US10745490B2
(en)
|
2014-04-11 |
2020-08-18 |
Celldex Therapeutics, Inc. |
Anti-ErbB antibodies and methods of use thereof
|
|
WO2016038609A1
(en)
*
|
2014-09-08 |
2016-03-17 |
Yeda Research And Development Co. Ltd. |
Anti-her3 antibodies and uses of same
|
|
WO2016038610A1
(en)
|
2014-09-08 |
2016-03-17 |
Yeda Research And Development Co. Ltd. |
Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (tki)
|
|
KR102390359B1
(ko)
*
|
2014-09-29 |
2022-04-22 |
삼성전자주식회사 |
폴리펩타이드, 이를 포함하는 항 VEGF 항체 및 항 c-Met/항 VEGF 이중 특이 항체
|
|
CN104861068B
(zh)
*
|
2015-01-23 |
2020-11-17 |
中国人民解放军军事科学院军事医学研究院 |
一种全人源抗her3抗体及其治疗相关疾病的用途
|
|
US10184006B2
(en)
|
2015-06-04 |
2019-01-22 |
Merrimack Pharmaceuticals, Inc. |
Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
|
|
WO2017062792A1
(en)
|
2015-10-07 |
2017-04-13 |
Obi Pharma, Inc. |
Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof
|
|
WO2017087547A1
(en)
*
|
2015-11-17 |
2017-05-26 |
Oncomed Pharmaceuticals, Inc. |
Pd-l1-binding agents and uses thereof
|
|
CA3004743A1
(en)
*
|
2015-11-24 |
2017-06-01 |
Cellerant Therapeutics, Inc. |
Humanized anti-cll-1 antibodies
|
|
KR101746152B1
(ko)
|
2015-12-07 |
2017-06-13 |
주식회사 이수앱지스 |
ＥｒｂＢ3에 특이적으로 결합하는 항체 및 그의 용도
|
|
MA43416A
(fr)
|
2015-12-11 |
2018-10-17 |
Regeneron Pharma |
Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
|
|
BR112018068512A2
(pt)
|
2016-03-15 |
2019-01-22 |
Merrimack Pharmaceuticals Inc |
métodos para tratar câncer de mama er+, her2-, hrg+ com o uso de terapias de combinação que compreendem um anticorpo anti-erbb3
|
|
WO2017219995A1
(zh)
|
2016-06-23 |
2017-12-28 |
江苏恒瑞医药股份有限公司 |
Lag-3抗体、其抗原结合片段及其医药用途
|
|
CN106692969B
(zh)
*
|
2016-12-08 |
2021-08-10 |
北海康成（北京）医药科技有限公司 |
抗erbb3抗体及其用途
|
|
CA3047833A1
(en)
*
|
2016-12-22 |
2018-06-28 |
Icahn School Of Medicine At Mount Sinai |
Anti-lilrb3 antibodies and methods of use thereof
|
|
CA3053749A1
(en)
|
2017-02-28 |
2018-09-07 |
Kinki University |
Method for treating egfr-tki-resistant non-small cell lung cancer by administration of anti-her3 antibody-drug conjugate
|
|
JOP20180021A1
(ar)
*
|
2017-03-16 |
2019-01-30 |
Janssen Biotech Inc |
الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها
|
|
EP3600421A4
(en)
*
|
2017-03-23 |
2021-01-06 |
The Trustees of The University of Pennsylvania |
ANTI-C5A ANTIBODIES AND USES OF THEM
|
|
CN113684275B
(zh)
*
|
2017-06-22 |
2024-02-27 |
北海康成（北京）医药科技有限公司 |
预测食管癌对抗erbb3抗体治疗的应答的方法和试剂盒
|
|
CN111093696B
(zh)
|
2017-07-17 |
2023-10-27 |
詹森生物科技公司 |
抗iii型纤连蛋白结构域的抗原结合区及其使用方法
|
|
EP3679070A1
(en)
*
|
2017-09-07 |
2020-07-15 |
Augusta University Research Institute, Inc. |
Antibodies to programmed cell death protein 1
|
|
WO2019076277A1
(zh)
*
|
2017-10-17 |
2019-04-25 |
江苏恒瑞医药股份有限公司 |
抗pd-1抗体和抗lag-3抗体联合在制备治疗肿瘤的药物中的用途
|
|
JOP20200215A1
(ar)
|
2018-03-05 |
2020-09-03 |
Janssen Pharmaceutica Nv |
الأجسام المضادة لـ PHF-Tau المضاد واستخداماتها
|
|
GB201804094D0
(en)
*
|
2018-03-14 |
2018-04-25 |
Ultrahuman Thirteen Ltd |
ERBB3 Binding agents
|
|
MX2020010094A
(es)
|
2018-04-06 |
2021-01-15 |
Dana Farber Cancer Inst Inc |
Kir3dl3 como receptor de hhla2, anticuerpos anti-hhla2 y usos de estos.
|
|
US20220072144A1
(en)
|
2018-09-20 |
2022-03-10 |
Daiichi Sankyo Company, Limited |
Treatment of her3-mutated cancer by administration of anti-her3 antibody-drug conjugate
|
|
WO2020163646A1
(en)
*
|
2019-02-08 |
2020-08-13 |
Igm Biosciences, Inc. |
Anti-gitr antigen-binding domains and uses thereof
|
|
WO2020214957A1
(en)
*
|
2019-04-19 |
2020-10-22 |
Tcrcure Biopharma Corp. |
Anti-pd-1 antibodies and uses thereof
|
|
CN118465272B
(zh)
*
|
2019-12-04 |
2025-08-19 |
珠海泰诺麦博制药股份有限公司 |
抗人巨细胞病毒抗体及其用途
|
|
US20230075244A1
(en)
*
|
2020-02-20 |
2023-03-09 |
The Feinstein Institutes For Medical Research |
Agonist antibodies against endoglin and uses thereof
|
|
US20240067738A1
(en)
*
|
2020-03-18 |
2024-02-29 |
Elanco Us Inc. |
Anti-il4 receptor antibodies for veterinary use
|
|
TW202227486A
(zh)
*
|
2021-01-04 |
2022-07-16 |
大陸商上海翰森生物醫藥科技有限公司 |
一種抗erbb3受體的抗體或其抗原結合片段及其醫藥用途
|
|
AU2023212994A1
(en)
|
2022-01-28 |
2024-08-08 |
Georgiamune Inc. |
Antibodies to programmed cell death protein 1 that are pd-1 agonists
|
|
CN114940714B
(zh)
*
|
2022-05-20 |
2023-06-16 |
湖南师范大学 |
肝癌标志物soat1单克隆抗体制备及其应用
|
|
CA3258344A1
(en)
|
2022-06-07 |
2023-12-14 |
Actinium Pharmaceuticals, Inc. |
CHELETARIANS AND BIFUNCTIONAL CONJUGATES
|
|
CN115109161B
(zh)
*
|
2022-06-28 |
2023-08-11 |
广东赛尔生物科技有限公司 |
含有间充质干细胞的减肥药物组合物
|
|
EP4637821A1
(en)
*
|
2022-12-23 |
2025-10-29 |
Actinium Pharmaceuticals, Inc. |
Her3 radioimmunotherapy for the treatment of solid cancers
|
|
CN118005795B
(zh)
*
|
2024-04-09 |
2024-06-28 |
天津旷博同生生物技术有限公司 |
一种抗人cd64抗体及应用
|